Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | GABRP | O00591 | 1/20 | 0.54 |
| ▸ | GABRD | O14764 | 1/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.54 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.54 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.54 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.54 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.54 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.54 |
| ▸ | GABRE | P78334 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.54 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.54 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.54 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11126760 | 0.97 | TSHR (0.56) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3709913 | 0.90 | TSHR (0.54) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3774341 | 0.89 | TSHR (0.65) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2146157 | 0.89 | SLC6A1 (0.52) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL2146162 | 0.89 | SLC6A1 (0.52) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL12862907 | 0.88 | TSHR (0.52) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL27508984 | 0.87 | TSHR (0.62) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL27430608 | 0.87 | TSHR (0.62) | TSHRGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1484884 | 0.87 | TSHR (0.62) | TSHRGABRPGABRDGABRA1GABRB1 | |
| Bromide SCHEMBL27312283 | 0.87 | TSHR (0.62) | TSHRGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815849-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | COLD SPRING HARBOR LABORATORY (US) | 2014-01-09 | — | — | US | disclosed |
| WO-2011142359-A1 | SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR | 日産化学工業株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
| CN-1040062-C | Pharmacologically active compounds, methods for the preparing thereof and compositions containing same | ORION YHTYMAE OY (FI) | 1998-10-07 | — | — | CN | disclosed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | disclosed |
| US-5283352-A | Transferase inhibitor | ORION-YHTYMA OY (FI) | 1994-02-01 | — | — | US | disclosed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
| CN-87108011-A | New compounds with pharmacological activity, preparation method and related components thereof | ORION YHTYMAE OY (FI) | 1988-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011862-A1 | Compositions and Methods for Treating Leukemia | MCL1, ABL1, FLT3 | TSHR 4763/4885GABRP 4644/4885GABRD 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.